GU Cancers 2021 | First-line ICIs in advanced non-clear cell RCC

Jeffrey Graham, MD, University of Manitoba, Winnipeg, Canada, describes a retrospective analysis evaluating the real-world effectiveness of first-line immune checkpoint inhibitor therapy in advanced non-clear cell renal cell carcinoma (nccRCC). Patient data was obtained from the International Metastatic RCC Database Consortium (IMDC), resulting in 1181 patients with nccRCC being included in the analysis and stratified based on first-line therapy received. The study suggested an association between first-line immune checkpoint blockade and improved overall survival compared to VEGF and mTOR targeted therapy. This interview took place during the 2021 Genitourinary Cancers Symposium.